Tracy L. Rose, MD, MPH, shares the immediate and direct impact of the long-term follow-up data from the JAVELIN Bladder 100 trial, an avelumab maintenance study in patients with advanced urothelial carcinoma, which was part of a poster session at the 2022 ASCO annual meeting. The results of the 38-month follow-up data showed prolonged overall survival in patients using first-line avelumab maintenance along with best supportive care who had not progressed during initial induction treatment with platinum-based chemotherapy.
Dr Rose also reviews survey results presented by Dr Shilpa Gupta that looked to define parameters on which patients would be considered "platinum-ineligible." These new consensus definitions will help guide first-line treatment decisions.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASCO 2022: Data for Better Decision-Making in the Treatment of Advanced Bladder Cancer - Medscape - Jun 27, 2022.